Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Myriam Curet Sells 408 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Myriam Curet sold 408 shares of Intuitive Surgical stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total value of $240,618.00. Following the sale, the executive vice president now directly owns 353 shares of the company’s stock, valued at $208,181.75. This trade represents a 53.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Intuitive Surgical Trading Down 0.7 %

NASDAQ ISRG traded down $4.05 during trading on Tuesday, reaching $591.65. 837,008 shares of the company’s stock were exchanged, compared to its average volume of 1,817,711. The firm has a market capitalization of $210.73 billion, a PE ratio of 92.30, a P/E/G ratio of 5.67 and a beta of 1.39. The company’s fifty day simple moving average is $555.91 and its 200-day simple moving average is $515.92. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00.

Hedge Funds Weigh In On Intuitive Surgical

Several hedge funds have recently bought and sold shares of ISRG. Bennett Selby Investments LP grew its holdings in Intuitive Surgical by 3.9% in the 4th quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 17 shares during the last quarter. Onefund LLC grew its holdings in shares of Intuitive Surgical by 1.9% during the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider’s stock worth $494,000 after purchasing an additional 18 shares in the last quarter. LVW Advisors LLC increased its position in shares of Intuitive Surgical by 1.3% during the fourth quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider’s stock valued at $756,000 after purchasing an additional 19 shares during the period. Wesbanco Bank Inc. raised its stake in shares of Intuitive Surgical by 1.6% in the fourth quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider’s stock valued at $635,000 after purchasing an additional 19 shares in the last quarter. Finally, FSM Wealth Advisors LLC lifted its position in Intuitive Surgical by 3.7% in the fourth quarter. FSM Wealth Advisors LLC now owns 526 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 19 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ISRG. Royal Bank of Canada upped their target price on Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. UBS Group upped their target price on Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partners upped their target price on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. Finally, Citigroup increased their target price on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.